Who owns what, and for how long — that is the first question on any deal touching the obesity-and-diabetes incretin franchise, and the answer lives in the patent record, not the press release. Eli Lilly holds method-of-use grants US12453758B2 (issued October 28, 2025) and the earlier US12295987B2 (issued May 13, 2025), both titled "Method of using a GIP/GLP1 co-agonist for diabetes" and both naming the same inventor team (Alsina-Fernandez, Cabrera, Coskun).
Per the grant type, this is the term-sheet distinction that matters: a method-of-use patent protects a particular way of using a compound, not the compound as a composition of matter. That is doing real work in any deal. When a counterparty licenses or options exposure to this franchise, the asset being conveyed is the right to a use, hemmed by the claim language — which is narrower than "we own the molecule." Confuse the two and you mis-price the deal.
Strip the spin and the structure follows from the document. The CPC classifications on both grants sit in A61K 38/26 (peptides for therapeutic use) and A61P 3/10 (antidiabetic), confirming the indication-specific framing. An acquirer paying for franchise durability is paying for the latest-issuing member of a family — the 2025 grants extend the protective envelope past the older foundational filings, which is exactly why continuation grants, not just the original, decide how long the cash flows are defensible.
What the documents do not settle is also a deal fact. A granted method-of-use claim does not foreclose a competitor's differently-claimed composition, and it says nothing about pricing, supply, or the compounding-pharmacy pressure that shadows the category. A patent is an exclusivity instrument, not a market forecast. Any model that treats the grant as a moat against all comers is reading more into the claims than the examiner allowed.
The disciplined read for a deals desk: name the specific grant a transaction leans on, check its issue date and claim type, and price the use it actually protects. Here, that is a GIP/GLP-1 co-agonist method for diabetes, owned by Lilly, freshly reinforced in 2025. Everything downstream — the upfront, the milestones, the royalty tier — should trace back to what that claim covers, and stop where it stops.